Adjuvant Radiotherapy or ET Lowers Locoregional Recurrence Rates Risk in Early

USA: Researchers have found in a new study that adjuvant radiotherapy (RT) or endocrine therapy (ET) significantly reduces the risk of locoregional recurrence (LRR) in patients with early-stage breast cancer and low genomic risk. The findings, published in JAMA Network Open by David Gibbes Miller from the Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, and colleagues, highlight the importance of treatment adherence and suggest the potential role of genomic biomarkers in guiding de-escalation strategies. The study addressed a critical question in breast cancer management: whether omission of RT or ET is associated with higher rates of recurrence among women with favorable tumor biology. Although treatment de-escalation is often considered for